Physician

Srijana Pradhan Bakshi, M.D

According to 2025 Medicare claims, Srijana Bakshi, M.D (NPI: 1972764520) practices rheumatology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES -MI PLLC (NPI: 1538655469; TIN: 823851171) and primary practice location at 48307-4599. Bakshi is affiliated with the POM ACO (ACO ID: A1297), Mosaic ACO (ACO ID: A5033), Collaborative ACO 30, LLC (ACO ID: A5483), and Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Bakshi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 300 traditional Medicare patients, billed 165,793 HCPCS/CPT codes, and received $1,860,067 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,453 prescription claims across 503 beneficiaries totaling $4,403,705 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 240 records totaling $8,743. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $669,400 to $1,860,067. Similarly, Part D prescription costs have risen steadily, from $258,455 to $4,403,705. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	478	19,841	$669,400
2016	516	19,775	$682,749
2017	218	4,539	$103,028
2018	223	4,082	$123,457
2019	224	9,893	$147,488
2020	122	7,519	$198,790
2021	116	12,826	$246,078
2022	103	9,964	$227,984
2023	284	57,202	$1,390,959
2024	300	165,793	$1,860,067

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	231	869	$258,455
2016	443	2,660	$1,422,632
2017	300	1,060	$533,458
2018	287	1,350	$926,263
2019	269	1,539	$1,773,960
2020	177	1,267	$1,388,197
2021	213	1,463	$2,393,519
2022	225	1,500	$3,111,866
2023	356	1,403	$2,763,535
2024	503	2,453	$4,403,705

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	75	75	$121
96413	Administration of chemotherapy into vein, 1 hour or less	62	308	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	216	397	$88
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	42	588	$53
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	196	334	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	97	2,774	$964,690
Otezla	Apremilast	105	3,270	$517,098
Enbrel Sureclick	Etanercept	47	1,318	$344,147
Taltz Autoinjector	Ixekizumab	35	1,350	$321,096
Cosentyx Sensoready (2 Pens)	Secukinumab	35	992	$261,010

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	239	$3,283	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$5,460	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Srijana Pradhan Bakshi, M.D?

Tedicare shows public-source Medicare data for Srijana Pradhan Bakshi, M.D (NPI 1972764520), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Srijana Pradhan Bakshi, M.D have ACO affiliation data?

Srijana Pradhan Bakshi, M.D is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), Mosaic ACO (MSSP, ACO ID A5033), Collaborative ACO 30, LLC (MSSP, ACO ID A5483), and Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to Srijana Pradhan Bakshi, M.D?

Srijana Pradhan Bakshi, M.D is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES -MI PLLC (billing NPI 1538655469) in the available physician profile data.

Does Srijana Pradhan Bakshi, M.D have Open Payments data?

Srijana Pradhan Bakshi, M.D has 240 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.